- Home
- BIRK vs ROIV Comparison
BIRK vs ROIV Comparison
Compare BIRK & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRK
- ROIV
- Stock Information
- Founded
- BIRK 1774
- ROIV 2014
- Country
- BIRK United Kingdom
- ROIV United Kingdom
- Employees
- BIRK N/A
- ROIV N/A
- Industry
- BIRK
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- BIRK
- ROIV Health Care
- Exchange
- BIRK Nasdaq
- ROIV Nasdaq
- Market Cap
- BIRK 9.4B
- ROIV 8.4B
- IPO Year
- BIRK 2023
- ROIV N/A
- Fundamental
- Price
- BIRK $56.47
- ROIV $10.94
- Analyst Decision
- BIRK Strong Buy
- ROIV Strong Buy
- Analyst Count
- BIRK 15
- ROIV 8
- Target Price
- BIRK $67.27
- ROIV $17.93
- AVG Volume (30 Days)
- BIRK 1.6M
- ROIV 5.3M
- Earning Date
- BIRK 02-20-2025
- ROIV 02-11-2025
- Dividend Yield
- BIRK N/A
- ROIV N/A
- EPS Growth
- BIRK 148.78
- ROIV N/A
- EPS
- BIRK 1.14
- ROIV 5.89
- Revenue
- BIRK $2,012,815,078.00
- ROIV $129,128,999.00
- Revenue This Year
- BIRK $20.02
- ROIV $15.98
- Revenue Next Year
- BIRK $17.04
- ROIV N/A
- P/E Ratio
- BIRK $49.64
- ROIV $1.86
- Revenue Growth
- BIRK 20.96
- ROIV 145.68
- 52 Week Low
- BIRK $41.00
- ROIV $9.69
- 52 Week High
- BIRK $64.78
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- BIRK 53.00
- ROIV 38.75
- Support Level
- BIRK $55.02
- ROIV $10.42
- Resistance Level
- BIRK $58.62
- ROIV $11.82
- Average True Range (ATR)
- BIRK 1.68
- ROIV 0.35
- MACD
- BIRK -0.51
- ROIV -0.11
- Stochastic Oscillator
- BIRK 23.77
- ROIV 29.21
About BIRK Birkenstock Holding plc
Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. The company operates in four operating segments based on its regional hubs: Americas, Europe and APMA (Asia Pacific, Middle East and Africa). The company sells its products through two main channels: business-to-business (B2B) and direct-to-consumer (DTC).
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.